Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Fulvestrant in FALCON trial improves PFS in advanced breast cancer

ESMO 2016

Published: 8 Oct 2016

Views: 2853

Rating:

Save

Dr Matthew Ellis - Washington University in St Louis, USA

Dr Ellis talks to ecancertv at ESMO 2016 about the finding that fulvestrant significantly increased progression-free survival in women with hormone-receptor-positive advanced breast cancer, and particularly those with less aggressive lower-volume disease.

Read the news story for more.

These results were also discussed by Prof John Roberston here.

Related Videos

OncoAlert round up July 28th to August 3rd, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert round up July 28th to August 3rd, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

SOFT study: Clinical relevance of genomic alterations in premenopausal HR+...

Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia

SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer ( Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )

Loco-regional management after neoadjuvant chemotherapy

Prof Terry Mamounas - Orlando Health Cancer Institute, Orlando, USA

Loco-regional management after neoadjuvant chemotherapy ( Prof Terry Mamounas - Orlando Health Cancer Institute, Orlando, USA )

Management of HER2 positive metastatic breast cancer treatment algorithm

Prof Sandra Swain - Georgetown University Medical Center, Washington DC, USA

Management of HER2 positive metastatic breast cancer treatment algorithm ( Prof Sandra Swain - Georgetown University Medical Center, Washington DC, USA )

Post neoadjuvant management in BRCA mutant breast cancer patients

Prof Banu Arun - MD Anderson Cancer Center, Houston, USA

Post neoadjuvant management in BRCA mutant breast cancer patients ( Prof Banu Arun - MD Anderson Cancer Center, Houston, USA )

Elacestrant shows improved PFS in ER-positive/HER2-negative mBC

Dr Virginia Kaklamani - UT Health San Antonio MD Anderson Cancer Center, San...

Elacestrant shows improved PFS in ER-positive/HER2-negative mBC ( Dr Virginia Kaklamani - UT Health San Antonio MD Anderson Cancer Center, San Antonio, USA )

A genomic assay may predict long-term prognosis in premenopausal patients with...

Dr Ruth O'Regan - University of Rochester, Rochester, USA

A genomic assay may predict long-term prognosis in premenopausal patients with HR+ early-stage breast cancer ( Dr Ruth O'Regan - University of Rochester, Rochester, USA )

Treatment decision guided by CTC count may improve long-term outcomes for mBC

Prof Jean-Yves Pierga - Institut Curie, Paris, France

Treatment decision guided by CTC count may improve long-term outcomes for mBC ( Prof Jean-Yves Pierga - Institut Curie, Paris, France )

Abemaciclib plus trastuzumab fulvestrant increased OS for HR+, HER2+ advanced...

Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA

Abemaciclib plus trastuzumab fulvestrant increased OS for HR+, HER2+ advanced breast cancer ( Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA )

More from ecancer